Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study to the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of IASO-782 in Patient With Systemic Lupus Erythematosus

NCT07483346 is registered in ClinicalTrials.gov with Shanghai IASO Biotechnology Co., Ltd as lead sponsor.

NCT NCT07483346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07483346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study to the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of IASO-782 in Patient With Systemic Lupus Erythematosus
Lead sponsor
Shanghai IASO Biotechnology Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
May 26, 2026
Completion date
May 31, 2028
Enrollment
20 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

sle - systemic lupus erythematosus